Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in Children and Adolescents With Moderate-to-severe Ulcerative Colitis or Crohn's Disease
NCT04844606Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2021
- Primary completion
- Dec 2030
- Countries
- 16
01
Overview
A Phase 3 trial of mirikizumab in ulcerative colitis (UC), Crohn's disease, sponsored by Eli Lilly and Company. Started May 2021; status: recruiting.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT04844606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04844606.